Active Biotech announces new direction
PRESS RELEASE
Lesen Sie auch
Lund Sweden, February 5, 2020 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that the Board of Directors, has approved a new direction for the company. This decision follows a
detailed opportunity analysis of the company’s wholly owned clinical lead assets, laquinimod and tasquinimod. Based on assessment of the many scientific publications and extensive pre-clinical and
clinical data accumulated, an analysis of the commercial attractiveness of different clinical indication opportunities to Active Biotech, as well as an external advisory challenge, new focused
target indications and corporate priorities have been defined.
Tasquinimod will be advanced in a new academic partnership, as an immunomodulatory product with a novel mechanism of action, for the treatment of multiple myeloma. Laquinimod will be advanced, as
an immunomodulatory product with a novel mechanism of action, for use as a topical agent in inflammatory eye diseases and as an oral treatment of patients with Crohn’s disease.
Going forward, Active Biotech has a project portfolio comprising naptumomab, partnered to NeoTX and currently in Phase 1b/2 for the treatment of advanced solid tumors, and the new clinical and
pre-clinical programs for tasquinimod and laquinimod.
No further work on the prior clinical programs within multiple sclerosis or Huntington’s disease for laquinimod or solid tumors for tasquinimod will be undertaken. In addition, Active Biotech will
for now put on hold the paquinimod and SILC-projects, to create a clear focus on the prioritized activities, and no further communication in relation to these assets is expected.
Opportunity analysis and new pipeline projects
Over the past 6 months, we have undertaken a detailed evaluation of tasquinimod and laquinimod from a technical as well as a
commercial perspective, to assess potential value-enhancing paths forward for the company in developing these assets. The analyses included updated scientific insights on the mechanism of action of
the compounds, as well as analyses of how best to leverage the existing clinical safety data. A broad network of international expert advisors has been engaged in this process, to ensure adequate
external challenge of ideas and directions developed. The new indications now being advanced for tasquinimod and laquinimod represent diseases with significant unmet medical need and commercial
potential where IP has been secured or filed.